| __timestamp | Dyne Therapeutics, Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1145000000 | 16606000 |
| Thursday, January 1, 2015 | 2028000000 | 21497000 |
| Friday, January 1, 2016 | 2281000000 | 25462000 |
| Sunday, January 1, 2017 | 2932000000 | 28195000 |
| Monday, January 1, 2018 | 24000 | 33078000 |
| Tuesday, January 1, 2019 | 271000 | 36523000 |
| Wednesday, January 1, 2020 | 700000 | 41455000 |
| Friday, January 1, 2021 | 1088000 | 74400000 |
| Saturday, January 1, 2022 | 3345000 | 101582000 |
| Sunday, January 1, 2023 | 2461000 | 112903000 |
Cracking the code
In the ever-evolving landscape of biotechnology, understanding cost structures is pivotal. This analysis delves into the cost of revenue trends for Veracyte, Inc. and Dyne Therapeutics, Inc. from 2014 to 2023. Over this period, Veracyte, Inc. has shown a steady increase in its cost of revenue, peaking at approximately $113 million in 2023, marking a significant growth of over 580% from 2014. In contrast, Dyne Therapeutics, Inc. experienced a volatile trajectory, with costs skyrocketing to $2.9 billion in 2017 before stabilizing to around $2.5 million in 2023. This stark contrast highlights the diverse financial strategies and market conditions influencing these companies. As the biotech sector continues to expand, these insights offer a glimpse into the financial health and strategic priorities of these industry players.
Analyzing Cost of Revenue: Eli Lilly and Company and Veracyte, Inc.
Cost of Revenue: Key Insights for AstraZeneca PLC and Veracyte, Inc.
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Veracyte, Inc.
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Veracyte, Inc.
Bio-Techne Corporation vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Catalent, Inc. vs Dyne Therapeutics, Inc.
Cost of Revenue: Key Insights for Sarepta Therapeutics, Inc. and Dyne Therapeutics, Inc.
Cost of Revenue: Key Insights for Walgreens Boots Alliance, Inc. and Veracyte, Inc.
Cost of Revenue Comparison: Jazz Pharmaceuticals plc vs Dyne Therapeutics, Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Veracyte, Inc.'s Expenses
Cost Insights: Breaking Down Veracyte, Inc. and Vericel Corporation's Expenses
Comparing Cost of Revenue Efficiency: Veracyte, Inc. vs Amphastar Pharmaceuticals, Inc.